| Bioactivity | Trontinemab is a bispecific and humanized IgG1-κ antibody, targeting to amyloid beta A4 precursor protein (APP) and transferrin receptor, p90, CD71 (TFRC). Trontinemab can be used for research on Alzheimer disease (AD)[1][2]. |
| Target | Amyloid beta A4 precursor protein, APP; Transferrin receptor, TFRC |
| Name | Trontinemab |
| CAS | 2568868-35-7 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Duggan MR, et al. Herpes Viruses in the Baltimore Longitudinal Study of Aging: Associations With Brain Volumes, Cognitive Performance, and Plasma Biomarkers. Neurology. 2022 Aug 19;99(18):e2014–24. [2]. Trontinemab. IMGT/mAb-DB. |